Skip to main content
SpringerLink
Log in

Rofecoxib Reduces Polyp Recurrence in Familial Polyposis

  • Published:
Digestive Diseases and Sciences Aims and scope Submit manuscript

Abstract

The long-term (mean of 16.4±4.2 months) efficacy and safety of rofecoxib (a specific COX-2 inhibitor) in maintaining the colon free of polyps in familial polyposis patients was assessed. Eight patients were treated with rofecoxib 25 mg every day. Sigmoidoscopy/colonoscopy was performed at study entry and every six months. At each endoscopy the number, size, and histological grade of all polyps were assessed, and the polyps were removed. The drug was well tolerated with no significant adverse events throughout the study. A highly significant reduction in the rate of polyp formation (70–100%) was observed in all patients from a mean number of 15.1±11.7 at baseline to 6.0±5.8 at one year and 1.6±1.6 at the end of follow-up (P =0.016 and 0.008, respectively). No patient developed cancer or high-grade adenoma. In conclusion, Long-term use of rofecoxib is well tolerated and effective in inhibiting polyp formation in polyposis patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Villavicencio RT, Rex DK: Colonic adenomas: prevalence and incidence rates, growth rates, and miss rates at colonoscopy. Semin Gastrointest Dis 11:185-193, 2000

    Google Scholar 

  2. Williams CS, Smalley W, DuBois RN: Aspirin use and potential mechanisms for colorectal cancer prevention. J Clin Invest 100:1325-1329, 1997

    Google Scholar 

  3. Ahnen DJ: Colon cancer prevention by NSAIDs: What is the mechanism of action? Eur J Surg; Suppl 582:111-114, 1998

    Google Scholar 

  4. Arber N: NSAIDs prevent colorectal cancer. Can J Gastroenterol 14:299-307, 2000

    Google Scholar 

  5. Wolfe MM, Lichtenstein DR, Singh G: Gastrointestinal toxicity of nonsteroidal anti-inflammatory drugs. N Engl J Med; 340:1888-1899, 1999

    Google Scholar 

  6. Kinzler KW, Nilbert MC, Su LK, Vogelstein B, Bryan TM, Levy DB, Smith KJ, Preisinger AC, Hedge P, McKechnie D: Identification of FAP locus genes from chromosome 5q21. Science 253:661-665, 1991

    Google Scholar 

  7. Heiskanen I, Jarvinen HJ: Fate of the rectal stump after colectomy and ileorectal anastomosis for familial adenomatous polyposis. Int J Colorectal Dis 12:9-13, 1997

    Google Scholar 

  8. Bullow C, Vasen H, Jarvinen H, Bjork J, Bisgaard ML, Bulow S: Ileorectal anastomosis is appropriate for a subset of patients with familial adenomatous polyposis. Gastroenterology 119:1454-1460, 2000

    Google Scholar 

  9. Waddell WR, Ganser GF, Cerise EJ, Loughry RW: Sulindac for polyposis of colon. Am J Surg 157:175-179, 1989

    Google Scholar 

  10. Cruz-Correa M, Hylind LM, Romans KE, Booker SV, Giardiello FM: Long-term sulindac therapy is effective in familial adenomatous polyposis. Gastroenterology 122:641-645, 2002

    Google Scholar 

  11. Giardiello FM, Hamilton SR, Krush AJ, Piantadosi S, Hylind LM, Celano P, Booker SV, Robinson CR, Offerhaus GJ: Treatment of colonic and rectal adenomas with Sulindac in familial adenomatous polyposis. N Engl J Med 328:1313-1316, 1993

    Google Scholar 

  12. Labayle D, Fisher D, Vielh P, Drouhin F, Pariente A, Bories C, Duhamel O, Trousset M, Attali P: Sulindac causes regression of rectal polyps in familial adenomatous polyposis. Gastroenterology 101:635-639, 1991.

    Google Scholar 

  13. Giardiello FM, Yang VW, Hylind LM, Krush AJ, Petersen GM, Trimbath JD, Piantadosi S, Garrett E, Geiman DE, Hubbard W, Offerhaus GJ, Hamilton SR: Primary chemoprevention of familial adenomatous polyposis with Sulindac. N Engl J Med 346:1054-1059, 2002

    Google Scholar 

  14. Hla T, Neilson K: Human cyclooxygenase-2 cDNA. Proc Natl Acad Sci USA 89:7384-7388, 1992

    Google Scholar 

  15. Eberhart CE, Coffey RJ, Radhika A, Giardiello FM, Ferrenbach S, DuBois RNl: Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 107:1183-1188, 1994

    Google Scholar 

  16. Marx J: Anti-inflammatory inhibits cancer growth—but now? Science 291:581-582, 2001

    Google Scholar 

  17. Reddy BS, Rao CV, Seibert K: Evaluation of cyclooxygenase-2 inhibitor for potential chemopreventive properties in colon carcinogenesis. Cancer Res 56:4566-4571, 1996

    Google Scholar 

  18. Oshima M, Dinchuk JE, Kargman SL, Oshima H, Hancock B, Kwong E, Trzaskos JM, Evans JF, Taketo MM: Suppression of intestinal polyposis in APC delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 87:803-809, 1996

    Google Scholar 

  19. Steinbach G, Lynch PM, Phillips RK, Wallace MH, Hawk E, Gordon GB, Wakabayashi N, Saunders B, Shen Y, Fujimura T, Su LK, Levin B: The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 342:1946-1952, 2000

    Google Scholar 

  20. Jacoby RF, Seibert K, Cole CE, Kelloff G, Lubet RA: The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the min mouse model of adenomatous polyposis. Cancer Res 60:5040-5044, 2000

    Google Scholar 

  21. Oshima M, Murai N, Kargman S, Arguello M, Luk P, Kwong E, Taketo MM, Evans JF: Chemoprevention of intestinal polyposis in the Apcdelta716 mouse by rofecoxib, a specific cyclooxygenase-2 inhibitor. Cancer Res 61:1733-1740, 2001

    Google Scholar 

  22. Cancer Therapy Evaluation Program: Common toxicity criteria. Bethesda, Maryland, National Cancer Institute, March 1998

  23. Altman DG: Practical Statistics for Medical Research. London, Chapman & Hall, 1990

    Google Scholar 

  24. Winde G, Schmid KW, Schlegel W, Fischer R, Osswald H, Bunte H: Complete reversion and prevention of rectal adenomas in colectomized patients with familial adenomatous polyposis by rectal low-dose sulindac maintenance treatment. Dis Colon Rectum 38:813-830, 1995

    Google Scholar 

  25. Tonelli F, Valanzano R, Messerini L, Ficari F: Long-term treatment with sulindac in familial adenomatous polyposis: is there an actual efficacy in prevention of rectal cancer? J Surg Oncol 74:15-20, 2000

    Google Scholar 

  26. Nugent KP, Farmer KC, Spigelman AD, Williams CB, Phillips RK: Randomized controlled trial of the effect of sulindac on duodenal and rectal polyposis and cell proliferation in patients with familial adenomatous polyposis. Br J Surg 80:1618-1619, 1993

    Google Scholar 

  27. Niv Y, Fraser GM: Adenocarcinoma in the rectal segment in familial polyposis coli is not prevented by sulindac therapy. Gastroenterology 107:854-857, 1994

    Google Scholar 

  28. Kaur BS, Khamnehei N, Iravani M, Namburu SS, Lin O, Triadafilopoulos G: Rofecoxib inhibits cyclooxygenase 2 expression and activity and reduces cell proliferation in Barrett's esophagus. Gastroenterology 123:60-67, 2002

    Google Scholar 

  29. Jeevaratnam P, Cottier DS, Browett PJ, Van De Water NS, Pokos V, Jass JR: Familial giant hyperplastic polyposis predisposing to colorectal cancer: A new hereditary bowel cancer syndrome. J Pathol 179:20-25, 1996

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Gastrointestinal Oncology Unit and the Departments of Gastroenterology and Pathology, Tel Aviv Sourasky Medical Center, Israel

    A. Hallak, L. Alon-Baron, M. Moshkowitz, Z. Halpern & N. Arber

  2. Pediatric Gastrointestinal Nutrition Unit, Rambam Medical Center, Israel

    R. Shamir

  3. Bruce Rappaport Faculty of Medicine, Haifa

    R. Shamir

  4. Merck Sharp & Dorhme–MSD, Petach-Tiqva, Israel

    B. Bulvik

  5. Sackler School of Medicine, Tel Aviv University, Tel Aviv

    E. Brazowski

Authors
  1. A. Hallak
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. L. Alon-Baron
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. R. Shamir
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M. Moshkowitz
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. B. Bulvik
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. E. Brazowski
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Z. Halpern
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. N. Arber
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to N. Arber.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hallak, A., Alon-Baron, L., Shamir, R. et al. Rofecoxib Reduces Polyp Recurrence in Familial Polyposis. Dig Dis Sci 48, 1998–2002 (2003). https://doi.org/10.1023/A:1026130623186

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1026130623186

Search

Navigation